x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

On The Pen GLP-1 News

Dave Knapp GLP-1 Industry Insider

On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 1% of all podcasts globally, and On The Pen is a top Substack best-seller.

health & fitness medicine

All Episodes

00:23:09

GLP-1 Access Is EXPLODING… But Something Else Is...

On The Pen GLP-1 News ·

2026/04/07

If you just look at the headlines, things look great for access to GLP-1 medications but for some of those already using these medications things are changing and getting tighter. Listen in as Dave breaks down the news of the week and puts it all in context.Topics:The GLP-1 paradox, Rise of telehealth powerhouses, FDA guidance on compounding, Enforcement risks and industry impact, Peptide imports and gray market concerns, New branded drug developments, Expansion of oral GLP-1 medications, New oral

en

01:13:34

Zepbound Dosing: What Your Doctor Didn't Explain

On The Pen GLP-1 News ·

2026/04/02

Are you on tirzepatide or semaglutide and struggled with inconsistent weight loss and side effects? On this episode of On The Pen, Dave Knapp and Dr. Ian Ellis dive into the surprising variability of GLP-1 dosing (retatrutide, tirzepatide), even when the weekly dose remains the same. We explore how these subtle dosage changes can lead to frustrating glp-1 side effects and why many individuals eventually give up on their weight loss medication. This new way of thinking about glp-1 dosing could change

en

00:18:48

Wegovy Price Drop Exposes a Bigger Problem

On The Pen GLP-1 News ·

2026/03/31

A major shift in obesity treatment is underway following a surprising pricing move that could change how patients access care. This episode explores the growing divide between traditional healthcare and alternative pathways, the real tradeoffs behind cost and safety, and what the future may hold for medications, access, and long term health.TOPICS:Wegovy Price Drop Changes EverythingWhat This Podcast CoversNew Savings Programs ExplainedWhy This Is Bigger Than PriceThe Broken Healthcare SystemRise of

en

26:23

Gray Market GLP-1 Is Booming Branded Access is Broken

On The Pen GLP-1 News ·

2026/03/03

Send a text Episode Summary (Short Version): This week on On The Pen, Dave breaks down the rapid changes reshaping GLP-1 access — from new federal reforms targeting PBMs and possible FDA limits on compounded semaglutide, to Walgreens and Amazon launching cash-pay weight loss clinics. As insurance denials continue and out-of-pocket costs rise, patients are stuck between a shifting policy landscape and a growing direct-to-consumer market. Plus, an AI-designed oral GLP-1 enters Phase 3 trials, s...

en

27:26

NEW GLP3 FROM NOVO NORDISK! BETTER THAN RETATRUTIDE?

On The Pen GLP-1 News ·

2026/02/24

Send a text This episode unpacks Novo’s aggressive price cuts, Lilly’s head to head trial win, and the emerging triple agonist race, revealing how pricing strategy and next generation data are colliding in a full scale GLP-1 market war. 00:00 – Cold Open: Lilly vs Novo Shock Timing Dave opens with the bombshell that Novo funded a tirzepatide trial while simultaneously announcing major price cuts to Wegovy and Ozempic, setting up a strategic chess match. 03:20 – Novo Nordisk Price Cuts Expla...

en

31:50

Compound Tirzepatide: Time to Stock Up?

On The Pen GLP-1 News ·

2026/02/10

Send a text This week on The Weekly Dose, Dave Knapp breaks down the biggest questions shaking up the GLP-1 world. From whether patients should be stocking up on compounded injectables, to what Eli Lilly’s earnings call revealed about Zepbound QuickPens, refill rules, and the long-awaited retatrutide timeline, this episode covers it all. Dave also unpacks FDA enforcement signals, the escalating tension between Big Pharma and compounders, the Hims & Hers controversy, and what recent lawsui...

en

21:35

Eli Lilly Earnings Call Q4 2025 Recap

On The Pen GLP-1 News ·

2026/02/04

Send us a text This week on On The Pen: The Weekly Dose, Dave breaks down one of the most consequential Eli Lilly earnings calls to date. We dive into major updates on retatrutide, new Phase 3 timelines, and why Lilly is positioning next-generation GLP-1 and GIP therapies far beyond obesity, including osteoarthritis, sleep apnea, addiction, and mental health. From manufacturing scale and Medicare access to brand-new molecules like bernipotide and amylin-based therapies, this episode explores ...

en

21:39

Once Monthly GLP-1 Injection? Pfizer Drops New Data

On The Pen GLP-1 News ·

2026/02/03

Send us a text This week on On The Pen: The Weekly Dose, we break down Pfizer’s $10 billion bet on obesity medicine and whether it’s shaping up to be a smart move or a costly miss. We dig into newly released Phase 2b data from Pfizer’s once-monthly GLP-1 candidate (formerly Metsera’s asset), what the results actually show, and how it stacks up in an increasingly crowded field that includes Novo Nordisk, Eli Lilly, and next-gen combination therapies. We also talk strategy, maintenance dosing, ...

en

19:29

A PCOS and Tirzepatide Trial. Finally

On The Pen GLP-1 News ·

2026/01/27

Send us a text Can Zepbound treat PCOS? That's the question this clinical trial will seek to answer, and we cover it exclusively on this week's On The Pen podcast. Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%! 🤝 Visit Our Sponsors! OTPLinks.com Decoding GLP-1 Book Decoding GLP-1: A Guide for Friends and Family of Those On The Pen Buy Here: https://amzn.to/3Dc66d4 MY WORK RELIES ON YOUR GENEROSITY, WAYS TO SUPPORT: Venmo: OnThePen Ca$h App: ManOnMounjaro BECOME A

en

21:02

Over The Counter GLP-1 Prediction

On The Pen GLP-1 News ·

2026/01/20

Send us a text In this episode of On The Pen: The Weekly Dose, Dave Knapp breaks down why the idea of over-the-counter GLP-1 medications isn’t radical speculation, it’s a pattern already in motion. Drawing on FDA signals, past regulatory precedent with Orlistat, recent pricing negotiations, softened safety language, and public comments from pharmaceutical executives, Dave lays out the case that low-dose oral GLP-1s could be the first step toward OTC access. This episode connects the dots betw...

en

31:48

GLP-1 PLUS Gastric Balloon for added Weight Loss!

On The Pen GLP-1 News ·

2026/01/19

Send us a text Shantanu Gaur, CEO of Allurion, returns to the podcast to break down their swallowable inflatable weight loss balloon, how it works, who it is for, how much it is expected to cost, and when patients can realistically expect access. We talk real world weight loss results, safety, availability in the US, and how Allurion fits into the broader obesity treatment conversation alongside GLP-1 medications and bariatric options. This is a clear, no hype discussion for patients who wa...

en

27:54

GLP-1 Access, MariTide Data, and the Oprah Effect on...

On The Pen GLP-1 News ·

2026/01/13

Send us a text This week on On The Pen, we break down a rare FDA walk-back on GLP-1 safety labeling, major pharma signals coming out of JPM 2026, and the growing tension between patient access and legislative efforts that could restrict compounding. We discuss what these developments actually mean for patients, why access—not innovation alone—will determine the future of obesity medicine, and how the OTP community continues to play a critical role in shaping this landscape. 🤝 Visit Our

en

26:11

Wegovy Pens Recalled & Wegovy Pill Launch

On The Pen GLP-1 News ·

2026/01/06

Send us a text This episode opens the year with one of the most consequential—and complicated—weeks in GLP-1 obesity medicine. We break down three stories that, taken together, reveal why patients are increasingly reading past headlines and demanding accountability from the industry. First, we examine early-phase trial data from Arrowhead Pharmaceuticals, after headlines claimed its experimental INHBE-targeting therapy “nearly doubled” the weight loss of Zepbound. We walk through what the dat...

en

00:29:14

Wegovy Pill Approved: First Ever GLP-1 Pill, As Good...

On The Pen GLP-1 News ·

2025/12/23

https://www.OTPLinks.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

en

00:59:05

GLP-1 Compound Legislation: States are the Next...

On The Pen GLP-1 News ·

2025/12/19

Pharma Influence & Why Patient Voices MatterLobbying Power: Eli Lilly, Novo Nordisk, and Government Access Why GLP-1 Medication Access Is at Risk Introducing Sabina Hemi & the Mission of GLP Winner Why Compounded GLP-1s Matter for Real Patients The Federal “Safe Drugs” Bill: What It Claims vs What It Does Why This Bill Raises Red Flags for Patients What Real Compounding Safety Reform Would Look Like How Compounding Pharmacies Are Actually Regulated Today Prescription Reporting vs Patient

en

00:29:09

Compounded Retatrutide? What the Judge Said

On The Pen GLP-1 News ·

2025/12/16

Retatrutide is years away from FDA approval and yet the fight over access, price, control of this medication is already well underway. That's what this podcast is going to be about today. There's well over a hundred thousand people by my estimates who are already on some form of this medication today. And that should tell you enough about how disruptive this molecule is and will be. It is a game changer among game changer. We've been talking about it for three years here at On The Pen, well before

en

00:50:24

Retatrutide Weight Loss: How Much At Each Dose

On The Pen GLP-1 News ·

2025/12/13

https://www.otplinks.com0:00 Welcome & today’s focus: Retatrutide and “chasing the biggest number” 1:11 On The Pen intro, live schedule (Mon/Wed/Fri) & housekeeping 2:10 How Dave first heard about retatrutide (work trip, early phase 1 data) 3:35 Flashback clip: early excitement about retatrutide phase 3 trials 4:40 Why this new retatrutide data feels different for obesity medicine 5:32 TRIUMPH-4 trial overview: obesity + knee osteoarthritis population 7:00 Headline results: 28.7% average

en

00:34:00

Mounjaro vs. New Obesity Drugs: Why Wave-007 Is...

On The Pen GLP-1 News ·

2025/12/09

Episode Timeline & Main Topics 00:00 — Opening & Community Update • First week doing the podcast fully live thanks to the On The Pen community • Overview of why this week’s news is a major turning point in obesity medicine 02:30 — Introducing the “One-and-Done” Obesity Drug (Wave Life Sciences) • WVE-007 early data drops • Why this therapy is unlike GLP-1s or any nutrient-stimulated hormone • Fat loss results and lean-mass increase 06:30 — How Wave-007 Works: INHBE Gene Silencing • Mechanism

en

00:29:39

GLP-1: New Metrics, New Molecules, New Prices

On The Pen GLP-1 News ·

2025/12/02

Topics We Cover:00:00 – New data from Harvard/Mass General may classify nearly 70% of adults as having obesity 03:00 – A new oral triple agonist shows record-setting absorption rates 07:00 – Fractal Health’s Revita procedure: weight maintenance after stopping GLP-1s 12:00 – Zepbound vial prices drop (full breakdown by dose) 16:00 – Dave’s personal experience switching off Mounjaro and intense hunger return 22:00 – Novo Nordisk’s EVOKE/EVOKE+ Alzheimer’s trial: what the data really means 29:00 – Why

en

00:36:28

Novo Nordisk Amycretin Shocker + Semaglutide Flopper

On The Pen GLP-1 News ·

2025/11/25

Follow Us Everywhere:https://www.otplinks.com Sign up for Emails: https://www.obesity.news Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

en

178 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown